Timucen 250 mg FC tablets
PDF Leaflet Revision Date: 30 October 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of essential hypertension.
Dosage (summary)
250 mg two or three times daily; usual dose 500 mg u2013 2 g daily.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; crosses placenta and appears in breast milk.
Key Drug Interactions
- Enhanced hypotensive effects with thiazide diuretics
- Lithium toxicity risk
- Diminished effects with sympathomimetics
Contraindications
- Hypersensitivity to methyldopa
- Impaired kidney or liver function
- Mental depression
- Acute liver disease
- Phaeochromocytoma
- Porphyria
Common side effects
- Drowsiness
- Nausea
- Dryness of the mouth
- Dizziness
- Weakness
Counselling Points
- Caution advised when driving
- Monitor for signs of liver dysfunction
- Report any unexplained fever
Serious warnings
- Periodic blood counts and liver function tests advised
- Severe hypotension during anaesthesia
Important Disclaimer
The Timucen 250 mg FC tablets professional information leaflet below is the property of Trinity Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
